Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim Light Conditions
| OCUPDelisted Stock | USD 1.13 0.06 5.04% |
Slightly above 62% of Ocuphire Pharma's investor base is looking to short. The analysis of current outlook of investing in Ocuphire Pharma suggests that many traders are alarmed regarding Ocuphire Pharma's prospects. Ocuphire Pharma's investing sentiment overview a quick insight into current market opportunities from investing in Ocuphire Pharma. Many technical investors use Ocuphire Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Ocuphire |
Phase 3 Startup Activities are Underway, with Trial Initiation Expected in Q1 2024FARMINGTON HILLS, Mich., Jan. 04, 2024 -- Ocuphire Pharma, Inc. , a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced it has received agreement from the U.S. Food and Drug Administration under a Special Protocol Assessment for the
Read at finance.yahoo.com
 |
Ocuphire Pharma Fundamental Analysis
We analyze Ocuphire Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Ocuphire Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Ocuphire Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Probability Of Bankruptcy
Probability Of Bankruptcy Comparative Analysis
Ocuphire Pharma is currently under evaluation in probability of bankruptcy category among its peers. Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
Ocuphire Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Ocuphire Pharma stock to make a market-neutral strategy. Peer analysis of Ocuphire Pharma could also be used in its relative valuation, which is a method of valuing Ocuphire Pharma by comparing valuation metrics with similar companies.
Peers
Ocuphire Pharma Related Equities
| FBIO | Fortress Biotech | 16.39 | ||||
| FBIOP | Fortress Biotech | 13.65 | ||||
| RVPH | Reviva Pharmaceuticals | 8.77 | ||||
| MBIO | Mustang Bio | 5.26 | ||||
| RNAZ | Transcode Therapeutics | 2.94 | ||||
| CKPT | Checkpoint Therapeutics | 2.57 | ||||
| KOD | Kodiak Sciences | 1.83 | ||||
| PLX | Protalix Biotherapeutics | 1.78 | ||||
| RIGL | Rigel Pharmaceuticals | 0.97 | ||||
| EYPT | Eyepoint Pharmaceuticals | 2.21 | ||||
| CGTX | Cognition Therapeutics | 2.44 | ||||
| SLS | Sellas Life | 3.42 | ||||
| RVPHW | Reviva Pharmaceuticals | 4.35 |
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in employment. You can also try the Bollinger Bands module to use Bollinger Bands indicator to analyze target price for a given investing horizon.
Other Consideration for investing in Ocuphire Stock
If you are still planning to invest in Ocuphire Pharma check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Ocuphire Pharma's history and understand the potential risks before investing.
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Aroon Oscillator Analyze current equity momentum using Aroon Oscillator and other momentum ratios | |
| Equity Valuation Check real value of public entities based on technical and fundamental data | |
| Portfolio Anywhere Track or share privately all of your investments from the convenience of any device | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |